PREDICTION OF THE COURSE OF OSTEOARTHROSIS FROM mTOR (MAMMALIAN TARGET OF RAPAMYCIN) GENE EXPRESSION

Четина, Е. В.; Bratygina, E A; Зайцева, Е. М.; Шарапова, Е. П.; Семенова, Л. А.; Demin, N. A.; Alekseyeva, L I; Glukhova, S.; Коломацкий, В. В.; Макаров, М. А.; Логунов, А. Л.; Роскидайло, А. А.; Макаров, С. А.

doi:10.14412/1995-4484-2012-500

Cited by 2 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Статисти-чески значимые различия по сравнению с контролем отме-чены звездочкой (*), между отдельными подгруппами больных -знаком (#). Амбулаторные больные ОА были разделены на две подгруппы: с НЭ и ВЭ гена mTOR [46,47]. При НЭ гена mTOR отмечалась значительно более сильная боль при ходьбе и стоя и более значительная скованность, чем при ВЭ mTOR (см.…”

Section: материал и методыunclassified

“…Профили экспрессии генов mTOR и AMПK в исследу-емых подгруппах больных ОА приводятся для сравнения, хотя эти данные были опубликованы ранее [46,47,54].…”

Section: результатыunclassified

“…Их можно разделить на подгруп-пы в соответствии с экспрессией гена mTOR -главного регулятора клеточного роста и пролиферации [46,47]. Низкая экспрессия (НЭ) этого гена в крови больных ОА ассоциировалась с более высокими показателями боли по сравнению с больными, имеющими высокую его экспрессию (ВЭ).…”

unclassified

See 2 more Smart Citations

Molecular mechanisms of pain regulation in patients with osteoarthritis

Chetina¹,

Маркова²,

Taskina³

et al. 2016

rsp

View full text Add to dashboard Cite

Section: материал и методыunclassified

Section: результатыunclassified

unclassified

See 1 more Smart Citation

Molecular mechanisms of pain regulation in patients with osteoarthritis

Chetina¹,

Маркова²,

Taskina³

et al. 2016

rsp

View full text Add to dashboard Cite

Rheumatic pain management: molecular aspects

Четина¹,

Шарапова²

2020

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Rheumatic diseases (RDs), including osteoarthritis and rheumatoid arthritis, are non-infectious slowly progressive incurable inflammatory diseases that lead to prolonged disability due to damage to the musculoskeletal system. Pain is a dominant symptom at any stage of these diseases, is directly related to joint functioning, and determines the quality of life in patients. Moreover, despite the significant successes of studying the role of inflammation and regulation of autoimmune processes, the pathogenetic mechanisms for the development and maintenance of pain in RDs are little investigated. The nociceptive mechanisms due to inflammation and/or joint structural impairment are involved in the development of rheumatic pain. In addition, the latter is also associated with impaired signaling in the nervous system and with psychological problems in patients.At the present stage, pain treatment includes non-pharmacological interventions, as well as the use of certain pharmacological agents, in particular opioids and narcotic drugs. However, despite significant successes in the design of drugs that relieve pain, at present, a significant proportion of patients with RDs still experience pain after therapy. When designing novel drugs for the treatment of pain, it is necessary to take into account the molecular mechanisms of its development in RDs. This review considers the features of the manifestations of pain, its molecular markers and mechanisms at different stages of the disease in patients with the two most common RDs, such as rheumatoid arthritis and osteoarthritis.

show abstract

PREDICTION OF THE COURSE OF OSTEOARTHROSIS FROM mTOR (MAMMALIAN TARGET OF RAPAMYCIN) GENE EXPRESSION

Cited by 2 publications

References 26 publications

Molecular mechanisms of pain regulation in patients with osteoarthritis

Molecular mechanisms of pain regulation in patients with osteoarthritis

Rheumatic pain management: molecular aspects

Contact Info

Product

Resources

About